Skip to Content
Merck
CN
All Photos(1)

Key Documents

View All Documentation

Safety Information

S-003

Supelco

R(-)-Selegiline solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Synonym(s):

(-)-Deprenyl

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C13H17N
CAS Number:
14611-51-9
Molecular Weight:
187.28
EC Number:
200-659-6
MDL number:
MFCD00672171
UNSPSC Code:
41116107
PubChem Substance ID:
329824408
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

C[C@@H](N(CC#C)C)CC1=CC=CC=C1

InChI

1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/m1/s1

InChI key

MEZLKOACVSPNER-GFCCVEGCSA-N

Gene Information

human ... MAOB(4129)

General description

A Certified Spiking Solution® suitable for use in LC/MS or GC/MS applications for clinical toxicology, forensic analysis, or urine drug testing. Selegiline is an antidepressant, which belongs to the phenethylamine class of drugs. It is sold under the trade names Anipryl®, Emsam®, and Zelapar® for treatment of Parkinson′s disease, depression, and senile dementia.

Legal Information

Anipryl is a registered trademark of Deprenyl Inc.
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Emsam is a registered trademark of Somerset Pharmaceuticals, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Zelapar is a registered trademark of Valeant Pharmaceuticals North America LLC

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Regulatory Information

危险化学品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jorge A Zavala et al.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 19(9), 1298-1299 (2012-06-23)
Pramipexole is a non-ergot dopamine agonist that is used frequently as a single therapy or in combination for the management of Parkinson's disease. Common side effects are daytime drowsiness, hypotension, hallucinations and compulsive behaviour. We describe a patient who developed
Dhaval R Kalaria et al.
International journal of pharmaceutics, 438(1-2), 202-208 (2012-09-08)
The objective was to investigate the anodal iontophoresis of the MAO-B inhibitors rasagiline (RAS) and selegiline (SEL) across porcine and human skin in vitro. Passive delivery of RAS and SEL from aqueous solution was minimal; however, increasing current density from
Retention rate of selegiline in early Parkinson's disease: a retrospective survey.
T Keränen et al.
International journal of clinical practice, 66(10), 1014-1014 (2012-09-22)
Wakako Maruyama et al.
Journal of neural transmission (Vienna, Austria : 1996), 120(1), 83-89 (2012-08-16)
Neuroprotection has been proposed in neurodegenerative disorders, such as Parkinson's and Alzheimer's diseases, to delay or halt disease progression or reverse neuronal deterioration. The inhibitors of type B monoamine oxidase (MAO), rasagiline and (-)deprenyl, prevent neuronal loss in cellular and
Chi-Un Pae et al.
The Journal of clinical psychiatry, 73(5), 661-668 (2012-06-16)
The objective of this analysis is to present the safety profile of selegiline transdermal system (STS) in clinical practice after US Food and Drug Administration approval by analyzing reported postmarketing adverse events (AEs). Deidentified data were obtained on AEs, regardless
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service